Sanofi (SNY) News Today $54.04 +1.89 (+3.61%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Sanofi board proposed dividend of EUR 3.92 for FY24January 30 at 8:15 AM | markets.businessinsider.comOppenheimer sets Alumis stock with Outperform, $32 targetJanuary 30 at 8:15 AM | msn.comSanofi expects earliest closing of Opella stake in Q2January 30 at 8:15 AM | markets.businessinsider.comSanofi reports Q4 IRFS EPS EUR 0.54January 30 at 8:15 AM | markets.businessinsider.comSanofi expects FY25 business EPS growth at LDD percentage at CERJanuary 30 at 8:15 AM | markets.businessinsider.comSanofi forecasts stronger profit growth, announces €5 billion stock buybackJanuary 30 at 8:15 AM | msn.comAnalysts Set Expectations for Sanofi FY2024 EarningsSanofi (NASDAQ:SNY - Free Report) - Equities researchers at Leerink Partnrs issued their FY2024 earnings estimates for Sanofi in a report issued on Monday, January 27th. Leerink Partnrs analyst D. Risinger forecasts that the company will post earnings per share of $3.77 for the year. The consensuJanuary 30 at 7:32 AM | marketbeat.comTeva on track for worst intraday loss in years on guidance missJanuary 30 at 3:14 AM | msn.comSanofi Q4 Business Net Income Declines; Net Sales Up 10.3% At CERJanuary 30 at 3:14 AM | markets.businessinsider.comSanofi meets estimates for fourth-quarter profit, plans 5 billion euros in buybacksJanuary 30 at 1:33 AM | reuters.comManning & Napier Advisors LLC Boosts Position in Sanofi (NASDAQ:SNY)Manning & Napier Advisors LLC raised its stake in Sanofi (NASDAQ:SNY - Free Report) by 4.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 280,881 shares of the company's stock after purchasing an additional 12,688January 29 at 10:46 AM | marketbeat.comTeva slips as 2025 earnings outlook misses estimatesJanuary 29 at 9:09 AM | msn.comTime To Be Bullish On Sanofi Ahead Of Its EarningsJanuary 29 at 9:09 AM | seekingalpha.comQ3 Earnings Estimate for Sanofi Issued By Leerink PartnrsSanofi (NASDAQ:SNY - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of Sanofi in a report issued on Monday, January 27th. Leerink Partnrs analyst D. Risinger expects that the company will post earnings of $1.57 per share foJanuary 29 at 6:24 AM | marketbeat.comInvestors Buy Large Volume of Sanofi Put Options (NASDAQ:SNY)January 29 at 2:14 AM | americanbankingnews.comSanofi (SNY) Expected to Announce Earnings on ThursdayJanuary 28 at 2:59 AM | americanbankingnews.comSanofi (SNY) Projected to Post Earnings on ThursdaySanofi (NASDAQ:SNY) will be releasing earnings before the market opens on Thursday, January 30, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=548546)January 28 at 2:57 AM | marketbeat.comZacks Research Has Positive Outlook for Sanofi Q1 EarningsSanofi (NASDAQ:SNY - Free Report) - Investment analysts at Zacks Research lifted their Q1 2025 EPS estimates for Sanofi in a research note issued to investors on Wednesday, January 22nd. Zacks Research analyst K. Shah now expects that the company will post earnings of $0.85 per share for the quarJanuary 28 at 1:45 AM | marketbeat.comNovo Nordisk settles Minnesota insulin pricing case: reportJanuary 27 at 3:36 PM | msn.comSanofi Target of Unusually High Options Trading (NASDAQ:SNY)Sanofi (NASDAQ:SNY - Get Free Report) was the recipient of unusually large options trading on Monday. Traders acquired 2,013 put options on the stock. This represents an increase of approximately 68% compared to the typical volume of 1,201 put options.January 27 at 10:38 AM | marketbeat.comEquities Analysts Offer Predictions for Sanofi Q1 EarningsJanuary 27 at 1:36 AM | americanbankingnews.comZacks Research Analysts Boost Earnings Estimates for SanofiSanofi (NASDAQ:SNY - Free Report) - Stock analysts at Zacks Research increased their Q1 2025 earnings per share estimates for Sanofi in a research report issued on Wednesday, January 22nd. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $0.85 for thJanuary 27 at 1:34 AM | marketbeat.comJanney Montgomery Scott LLC Increases Stock Holdings in Sanofi (NASDAQ:SNY)Janney Montgomery Scott LLC increased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 5.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 327,631 shares of the company's stock after purchasing an additional 1January 26, 2025 | marketbeat.comZacks Research Predicts Sanofi's Q3 Earnings (NASDAQ:SNY)January 26, 2025 | americanbankingnews.comPharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi DrugJanuary 24, 2025 | msn.comSound Income Strategies LLC Raises Position in Sanofi (NASDAQ:SNY)Sound Income Strategies LLC grew its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 156,520.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 67,347 shares of the company's stock after acquiring an additional 67,304 shares during the period.January 24, 2025 | marketbeat.comZacks Research Comments on Sanofi's Q3 Earnings (NASDAQ:SNY)Sanofi (NASDAQ:SNY - Free Report) - Zacks Research raised their Q3 2025 earnings estimates for Sanofi in a research note issued on Wednesday, January 22nd. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $1.59 for the quarter, up from their prior foJanuary 24, 2025 | marketbeat.comSanofi Advances with Cialis Trial and EU Approval for SarclisaJanuary 24, 2025 | tipranks.comBaker Ellis Asset Management LLC Sells 5,281 Shares of Sanofi (NASDAQ:SNY)Baker Ellis Asset Management LLC lessened its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 5.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 86,908 shares of the company's stock after selling 5,281 shares duJanuary 23, 2025 | marketbeat.comSanofi (SNY) Expected to Announce Quarterly Earnings on ThursdaySanofi (NASDAQ:SNY) will be releasing earnings before the market opens on Thursday, January 30, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=548546)January 23, 2025 | marketbeat.comSanofi’s Framingham facility hit with FDA warningJanuary 22, 2025 | bizjournals.comSanofi gets EU approval for Sarclisa for newly diagnosed patientsJanuary 22, 2025 | msn.comHB Wealth Management LLC Grows Position in Sanofi (NASDAQ:SNY)HB Wealth Management LLC grew its stake in Sanofi (NASDAQ:SNY - Free Report) by 151.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,496 shares of the company's stock after acquiring an additiJanuary 22, 2025 | marketbeat.comPress Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myelomaJanuary 22, 2025 | globenewswire.comSanofi says FDA lifted clinical hold on trial for Cialis OTC switchJanuary 21, 2025 | msn.comPress Release: Opella reaches study milestone for CialisJanuary 21, 2025 | globenewswire.comRitholtz Wealth Management Decreases Stake in Sanofi (NASDAQ:SNY)Ritholtz Wealth Management reduced its stake in Sanofi (NASDAQ:SNY - Free Report) by 17.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,559 shares of the company's stock after selling 8,692 shares during the periJanuary 19, 2025 | marketbeat.comSanofi (NASDAQ:SNY) Shares Bought by Park Avenue Securities LLCPark Avenue Securities LLC increased its holdings in Sanofi (NASDAQ:SNY - Free Report) by 14.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 68,982 shares of the company's stock after acquiring an additional 8,615 shaJanuary 17, 2025 | marketbeat.comInsulin prices have dropped but some poor patients are paying more, NYT saysJanuary 16, 2025 | markets.businessinsider.comPines Wealth Management LLC Invests $247,000 in Sanofi (NASDAQ:SNY)Pines Wealth Management LLC bought a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,072 shares of the company's stock, valued atJanuary 16, 2025 | marketbeat.comKymera rises after presentation at the J.P. Morgan eventJanuary 14, 2025 | msn.comSanofi (SNY) CEO Paul Hudson Hosts 43rd Annual J.P. Morgan Healthcare (Transcript)January 14, 2025 | seekingalpha.comSanofi Advances Multiple Myeloma Treatment with Sarclisa InnovationsJanuary 14, 2025 | tipranks.comSanofi's Sarclisa Gets First Approval In China For Relapsed Or Refractory Multiple Myeloma In AdultsJanuary 13, 2025 | markets.businessinsider.comPress Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaJanuary 13, 2025 | globenewswire.comIGM Biosciences price target lowered to $2 from $12 at TruistJanuary 10, 2025 | markets.businessinsider.comSanofi: Underappreciated Powerhouse Primed For Long-Term Growth (Rating Upgrade)January 10, 2025 | seekingalpha.comVir Biotech upgraded at Morgan Stanley on cancer drug dataJanuary 9, 2025 | msn.comSanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple MyelomaJanuary 9, 2025 | benzinga.comPress Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myelomaJanuary 9, 2025 | globenewswire.com Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Email Address SNY Media Mentions By Week SNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNY News Sentiment▼0.880.76▲Average Medical News Sentiment SNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNY Articles This Week▼4113▲SNY Articles Average Week Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NVO News AZN News NVS News GSK News TAK News ARGX News BNTX News TEVA News BGNE News SMMT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNY) was last updated on 1/30/2025 by MarketBeat.com Staff From Our Partners#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredHot Stock Alert! Biotech innovator on the NYSE announces breakthrough antiviral therapyA revolutionary antiviral drug is here! This breakthrough could mean viruses are unlikely to escape treatment....Smallcaps Daily | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.